What is NUT carcinoma?
NUT carcinoma is a rare and very aggressive cancer defined by a specific gene change involving the NUTM1 gene. It was formerly called NUT midline carcinoma, because it usually grows in structures along the middle of the body.
The most common sites are the head and neck, especially the nose and sinuses, and the chest, including the lungs and mediastinum (the space between the lungs).
NUT carcinoma can occur at any age, but it affects children, teenagers and young adults more often than most carcinomas. Unlike many head and neck or lung cancers, it is not linked with smoking, alcohol or HPV.
NUT carcinoma grows quickly and is often diagnosed at an advanced stage. Its outlook is poor, but some people, particularly those whose tumour can be completely removed, do much better (Chau et al., 2016).
Because NUT carcinoma looks like other poorly differentiated cancers under the microscope, it is probably under-diagnosed. Some cases are first reported as squamous cell carcinoma, undifferentiated carcinoma or even a small round cell sarcoma. Experts recommend that pathologists test for it more widely (Luo et al., 2025).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Poorly differentiated carcinoma with squamous features |
| Defining change | NUTM1 gene rearrangement (most often BRD4::NUTM1) |
| How common | Rare, but probably under-recognised |
| Typical age | Any age; median about 20-30 |
| Main sites | Head and neck (nose, sinuses, salivary glands, larynx) and chest (lung, mediastinum) |
| Main test | NUT protein staining on the biopsy |
| Main treatment | Surgery, radiotherapy and chemotherapy; clinical trials |
| Outlook | Median survival under a year in most series; better after complete surgery |
2. How NUT carcinoma develops
The NUTM1 gene is normally active only in the testis. In NUT carcinoma, a chromosome break joins NUTM1 to another gene, creating a fusion gene (French et al., 2014; French et al., 2022).
The fusion protein holds the cell in an immature, rapidly dividing state, mainly by switching on growth genes such as MYC.
| Fusion | Approximate share | Notes |
|---|---|---|
| BRD4::NUTM1 | About 70-75% | Most common; often the most aggressive |
| BRD3::NUTM1 | About 15% | May have a slightly better outlook |
| NSD3::NUTM1 | About 5-10% | May have a slightly better outlook |
| Other partners | A few per cent | Rare |
Causes and risk factors
The cause of the fusion is not known. It is not inherited and is not linked with lifestyle factors.
| Factor | Known link? |
|---|---|
| Smoking | No |
| Alcohol | No |
| HPV or Epstein-Barr virus | No |
| Family history | No |
| Age | Can occur from infancy to old age |
3. How does it look
Under the microscope
NUT carcinoma consists of sheets of small to medium-sized, uniform, undifferentiated cells. Many tumours show abrupt keratinisation: sudden islands of mature squamous cells among the immature cells.
The key test is immunohistochemistry for NUT protein. More than half of the tumour cell nuclei show a speckled brown staining pattern, and this finding is diagnostic.
The fusion can also be confirmed with FISH or RNA sequencing.
| Look-alike tumour | How NUT carcinoma differs |
|---|---|
| Poorly differentiated squamous cell carcinoma | Positive NUT stain; younger patients; no smoking or HPV link |
| Sinonasal undifferentiated carcinoma | Positive NUT stain |
| Ewing sarcoma and other small round cell tumours | Positive NUT stain and keratin |
| Lymphoma | Keratin-positive, lymphoid markers negative |
| Germ cell tumour | Different markers; NUT stain positive |
The tumour itself
NUT carcinoma usually forms a large, fast-growing mass that invades nearby structures. Areas of dead tissue (necrosis) are common.
On scans
| Site | Typical findings |
|---|---|
| Nose and sinuses | A mass destroying bone, sometimes growing into the eye socket or skull base |
| Lung | A large central mass, often with enlarged lymph nodes and fluid around the lung |
| Mediastinum | A mass in the middle of the chest pressing on airways or blood vessels |
| Spread | Bones, lymph nodes, lungs, liver and pleura, best shown by PET-CT |
Visible signs
| Sign | What it looks like |
|---|---|
| Facial swelling | Over the cheek, around the eye or near the nose |
| Bulging or displaced eye | From a sinus tumour growing into the eye socket |
| Neck lump | An enlarged lymph node or a tumour of the thyroid or salivary gland |
| Swollen face and neck veins | From a chest tumour pressing on the large vein to the heart (superior vena cava obstruction) |
| Weight loss | In advanced disease |
4. Symptoms
Symptoms depend on where the cancer starts. Because the tumour grows quickly, symptoms often worsen over weeks.
Head and neck
- Blocked nose, usually on one side
- Nosebleeds
- Facial pain, swelling or numbness
- Bulging eye, double vision or watery eye
- Headache
- Neck lump
- Hoarse voice or difficulty swallowing, for tumours of the larynx or throat
Chest
- Persistent cough, sometimes with blood
- Chest pain
- Shortness of breath
- Swelling of the face, neck and arms if the tumour presses on the superior vena cava
- Fever, night sweats and weight loss
Spread to other areas
- Bone pain, especially in the back
- Tiredness and loss of appetite
When to seek medical advice
See a doctor promptly if you have a one-sided blocked nose with bleeding, facial swelling, a neck lump or a cough that does not go away, especially if symptoms are getting worse.
Seek urgent help for breathlessness, swelling of the face and neck, or coughing up blood.
5. Diagnosis
| Test | Purpose |
|---|---|
| Biopsy | Essential; ideally a generous tissue sample |
| NUT immunohistochemistry | Diagnostic when strongly positive |
| FISH or RNA sequencing | Confirms NUTM1 rearrangement and identifies the fusion partner |
| CT and MRI of the primary site | Show the size and local extent |
| PET-CT | Checks for spread throughout the body |
| MRI of the brain | If symptoms suggest spread |
| Endoscopy or bronchoscopy | To examine and sample the nose, throat or airways |
NUT carcinoma is staged using the same system as other cancers at the same site, for example head and neck or lung staging.
6. Treatment
NUT carcinoma should be treated at a specialist cancer centre with experience of rare tumours. Many experts recommend starting treatment quickly, because the cancer can progress within weeks.
International groups have published guidance on diagnosis and treatment (Zhang et al., 2026).
Surgery
Complete surgical removal with clear margins is linked with the best outcomes, particularly for head and neck tumours (Chau et al., 2016; Giridhar et al., 2018). Surgery may be done at the start or after chemotherapy has shrunk the tumour.
Radiotherapy
High-dose radiotherapy to the tumour area is usually given after surgery or as the main local treatment when surgery is not possible. It is often combined with chemotherapy.
Chemotherapy
| Approach | Details |
|---|---|
| Sarcoma-type regimens | Ifosfamide-based combinations, sometimes used as in Ewing sarcoma |
| Platinum-based regimens | Cisplatin or carboplatin with other drugs, as used in squamous cell carcinoma |
| Taxanes | Often added in combination |
Responses to chemotherapy are often short-lived, so it is usually combined with surgery and radiotherapy.
Newer treatments
| Treatment | Status |
|---|---|
| BET inhibitors | Target the BRD4 part of the fusion; some responses in trials, though side effects and short responses are a problem (Stathis and Bertoni, 2018) |
| Combinations with BET inhibitors | Being tested with chemotherapy and other targeted drugs |
| CDK9 and p300 inhibitors | Early research |
| Immunotherapy | Being studied; occasional responses reported |
| Clinical trials | Strongly recommended |
Why treatment is combined
No single treatment controls NUT carcinoma reliably on its own. Most specialists therefore plan all three treatments together from the start: chemotherapy to shrink the tumour and treat hidden spread, surgery to remove the tumour completely where possible, and radiotherapy to reduce the risk of the cancer returning in the same place.
The exact order depends on the site and size of the tumour. For example, a small sinus tumour may be removed first, while a large chest tumour may be treated with chemotherapy first.
Supportive care
| Problem | Support |
|---|---|
| Pain | Pain specialists and palliative care teams |
| Breathing problems | Stents, drainage of fluid or radiotherapy |
| Eating and swallowing | Dietitians and speech therapists |
| Emotional impact | Psychologists and support groups, especially for young people |
Early involvement of a palliative care team helps control symptoms. It can be offered alongside active treatment from the start.
7. Outlook (prognosis)
NUT carcinoma has a poor outlook overall. In large series, the median survival is about 6-10 months (Bauer et al., 2012; Chau et al., 2020).
Some patients, however, survive for many years, particularly when the tumour is found early and removed completely.
| Factor | Effect |
|---|---|
| Head and neck site | Better outlook than chest tumours |
| Non-BRD4 fusion (BRD3 or NSD3) | Better outlook in some studies |
| Complete surgical removal | Strongest link with long-term survival |
| Chest primary or spread at diagnosis | Poorer outlook |
| Rapid start of combined treatment | May improve outcomes |
A prognostic model based on the site of the tumour and the fusion type can help doctors estimate outlook (Chau et al., 2020).
NUT carcinoma in children and teenagers
NUT carcinoma is one of the few carcinomas that occurs regularly in children and adolescents. Young patients are usually treated by paediatric or teenage and young adult cancer teams, working with head and neck or thoracic specialists.
Treatment is often based on intensive regimens used for sarcomas, together with surgery and radiotherapy. Families are offered the same support services as for other childhood cancers.
Follow-up after treatment
| Time after treatment | Typical follow-up |
|---|---|
| First 2 years | Clinic visits and scans every 2-3 months, as most relapses happen early |
| Years 3-5 | Visits and scans every 3-6 months |
| After 5 years | Yearly review, including late effects of radiotherapy and chemotherapy |
Late effects can include dry mouth, swallowing difficulties, hormone changes after head and neck radiotherapy, and lung or heart effects after chest treatment.
Registries and research
Because NUT carcinoma is rare, every patient adds valuable knowledge. An international NUT carcinoma registry collects information and tissue to improve understanding and treatment. Your team can explain how to take part.
8. Living with NUT carcinoma
- Ask for a second opinion at a centre familiar with NUT carcinoma
- Ask about trials and the international NUT carcinoma registry
- Plan treatment quickly, because delays matter
- Look after nutrition, especially during head and neck radiotherapy
- Seek emotional support for yourself and your family
- Keep copies of your pathology report, including the fusion type, to share with other doctors
9. Frequently asked questions
| Question | Answer |
|---|---|
| Is NUT carcinoma related to smoking? | No |
| Why is it called NUT? | NUT stands for “nuclear protein in testis”, the normal role of the NUTM1 gene |
| Is it inherited? | No |
| Why was my cancer first called something else? | It can look like other undifferentiated cancers until the NUT stain is done |
| Can it be cured? | Long-term survival is possible, mainly after complete surgery with radiotherapy |
| Can children get NUT carcinoma? | Yes. It is one of the few carcinomas seen regularly in children and teenagers |
| Should my tumour be retested? | If you were diagnosed with an undifferentiated or squamous cancer at a young age without smoking, ask whether NUT testing was done |
| How quickly should treatment start? | As soon as possible, ideally within days to a few weeks of diagnosis |
10. Questions to ask your care team
- Has the diagnosis been confirmed by NUT staining or genetic testing?
- Which fusion partner does my tumour have?
- Can the tumour be completely removed?
- What combination of surgery, radiotherapy and chemotherapy do you recommend?
- Are there clinical trials I can join?
- Who can help with symptoms and support?
Resources
- French, C.A. et al. (2014) ‘NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism’, Cancer Discovery, 4(8), pp. 928-941.
- French, C.A. et al. (2022) ‘Report of the first international symposium on NUT carcinoma’, Clinical Cancer Research, 28(12), pp. 2493-2505.
- Bauer, D.E. et al. (2012) ‘Clinicopathologic features and long-term outcomes of NUT midline carcinoma’, Clinical Cancer Research, 18(20), pp. 5773-5779.
- Chau, N.G. et al. (2016) ‘Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck’, Cancer, 122(23), pp. 3632-3640.
- Chau, N.G. et al. (2020) ‘An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients’, JNCI Cancer Spectrum, 4(2), p. pkz094.
- Giridhar, P. et al. (2018) ‘Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases’, European Archives of Oto-Rhino-Laryngology, 275(3), pp. 815-821.
- Stathis, A. and Bertoni, F. (2018) ‘BET proteins as targets for anticancer treatment’, Cancer Discovery, 8(1), pp. 24-36.
- Luo, J. et al. (2025) ‘Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck’, Nature Reviews Clinical Oncology, 22(4), pp. 292-306.
- Zhang, Y. et al. (2026) ‘International guidelines on the diagnosis and treatment of NUT carcinoma’, The Innovation, 7(1), p. 101068.
Prepared by the editorial team, October 2026.